Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYT X300
- Development stage
- Preclinical
- Lead developer
- Cytospire Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CYT X300 is a pan-gamma delta T cell engager (TCE) being developed by Cytospire Therapeutics for the treatment of EGFR-positive solid tumors. Unlike conventional T cell engagers that typically target the CD3 epsilon chain on alpha-beta T cells, CYT X300 is designed to recruit and activate the entire pool of gamma delta T cells. This approach aims to generate a broader anti-tumor immune response while potentially offering a superior safety profile, specifically by reducing the risk of systemic cytokine release syndrome (CRS) often associated with CD3-based engagers. As of early 2024, the program is in IND-enabling preclinical studies following a significant Series A financing round led by 4BIO Capital.
02
Targets
EGFR (Epidermal growth factor receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on CYT X300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYT X300.